Welcome to our dedicated page for Moderna news (Ticker: MRNA), a resource for investors and traders seeking the latest updates and insights on Moderna stock.
Moderna, Inc. (NASDAQ: MRNA) is a biotechnology company focused on mRNA medicines, with multiple approved vaccines and a broad clinical pipeline. The MRNA news page on Stock Titan aggregates company announcements, investor updates and regulatory developments so readers can follow how Moderna’s strategy and pipeline progress translate into real-world events.
Investors and observers can use this feed to track commercial updates on products such as Spikevax, mRESVIA and mNEXSPIKE, along with developments in late-stage respiratory programs like the seasonal influenza vaccine mRNA-1010, the flu/COVID combination vaccine mRNA-1083 and the Norovirus vaccine candidate mRNA-1403. News items often cover regulatory submissions and opinions from agencies including the U.S. Food and Drug Administration, the European Medicines Agency, Health Canada and others.
The page also surfaces pipeline and clinical trial news in oncology and rare diseases, including updates on mRNA-4157 (intismeran autogene), mRNA-4359, mRNA-3927 for propionic acidemia and mRNA-3705 for methylmalonic acidemia. Announcements related to partnerships, such as CEPI’s funding commitment for the H5 pandemic influenza vaccine candidate mRNA-1018, appear here as well.
In addition, the MRNA news feed includes financial results, guidance and capital structure updates, such as quarterly earnings releases, multi-year financial frameworks and information on facilities like the $1.5 billion credit agreement. Corporate items, including participation in healthcare conferences, Analyst Day presentations and shareholder meeting outcomes, are also reflected.
By reviewing this consolidated news stream, readers can see how Moderna’s respiratory vaccine franchise, oncology and rare disease programs, manufacturing expansion and financing decisions evolve over time, all based on the company’s own disclosures and related announcements.
Moderna, Inc. (Nasdaq: MRNA) announced supply agreements for its COVID-19 Vaccine Moderna with Taiwan (5 million doses) and Colombia (10 million doses). Deliveries are set to commence in mid-2021, pending regulatory approvals in both countries. The vaccine is based on mRNA technology and has received various authorizations globally. Moderna emphasizes collaboration with both governments in this effort.
Moderna (Nasdaq: MRNA) will host a live conference call on February 25, 2021, at 8:00 a.m. ET to discuss its fourth quarter and full year 2020 financial results. The call can be accessed by dialing 866-922-5184 domestically or 409-937-8950 internationally, with conference ID 4066945. Moderna has evolved significantly over the past ten years, moving from research-stage activities to commercial success, primarily recognized for its COVID-19 vaccine, now widely used. The company has 24 development programs, with 13 in clinical stages across various therapeutic areas.
Moderna, Inc. (Nasdaq: MRNA) has received interim authorization from the Singapore Health Sciences Authority for its mRNA COVID-19 vaccine under the Pandemic Special Access Route. This decision marks a significant milestone in the global COVID-19 response. The authorization is based on extensive scientific evidence, including data from its pivotal Phase 3 clinical trial. Moderna's vaccine is already approved in several countries, including the U.S., Canada, and the EU. The company continues to advance mRNA technology for various therapeutic areas, supported by strategic alliances with major pharmaceutical firms.
Moderna (Nasdaq: MRNA) announced an increase in its COVID-19 vaccine supply agreement with the Swiss Federal Government from 7.5 million to 13.5 million doses. This decision underscores the government's confidence in Moderna, with deliveries starting in summer 2021 and an option for additional doses in early 2022. The vaccine was authorized by Swissmedic, supporting Moderna's expansion strategy beyond North America. The company continues to enhance its mRNA vaccine platform, which has gained regulatory approval and shows promise in various therapeutic areas.
Moderna (Nasdaq: MRNA) is in discussions with the U.S. government for an additional 100 million doses of its COVID-19 vaccine, aiming for delivery in Q3 2021. This new agreement would increase the total doses to 300 million. Moderna leverages its U.S. manufacturing capacity to fulfill this order. The vaccine received Emergency Use Authorization from the FDA on December 18, 2020, and has been pivotal in the fight against the pandemic. However, the press release includes various safety considerations and potential risks associated with vaccine administration.
Moderna, Inc. (Nasdaq: MRNA) has supplied 30.4 million doses of its COVID-19 vaccine to the U.S. government, with 10.1 million administered in the country. The company is on track to deliver 100 million doses by the end of Q1 2021 and 200 million total by the end of Q2 2021. Moderna has increased its global production estimate for 2021 from 500 to 600 million doses, aiming for up to 1 billion doses. The vaccine has received Emergency Use Authorization from the FDA, and additional authorizations are pending in other countries.
Moderna, Inc. (Nasdaq: MRNA) announced a conference call on January 25 at 4:30 PM ET to discuss in vitro neutralization studies of its COVID-19 vaccine against emerging SARS-CoV-2 strains. The findings indicate that the vaccine retains neutralizing activity, a critical factor in ongoing pandemic response efforts. The call will also be accessible via a webcast. Over the past decade, Moderna has evolved significantly, demonstrating its mRNA technology's potential with multiple vaccines and therapies in development, enhancing its position in the biotechnology field.
Moderna (Nasdaq: MRNA) announced in vitro neutralization data for its COVID-19 Vaccine against emerging variants B.1.1.7 and B.1.351. The vaccine demonstrated strong neutralizing titers against B.1.1.7, with no significant decline. However, a six-fold reduction was observed against B.1.351, although levels remained protective. The company plans to conduct a Phase 1 trial for an emerging variant booster candidate, mRNA-1273.351. CEO Stéphane Bancel emphasized the importance of being proactive against evolving virus strains.
Moderna Inc (Nasdaq: MRNA) has initiated a Phase 1/2 clinical trial for its COVID-19 vaccine candidate (mRNA-1273 or TAK-919) in Japan, in partnership with Takeda Pharmaceutical Co. The study will involve 200 healthy adults and will assess the vaccine's safety and immunogenicity. Participants will receive two vaccinations 28 days apart. Pending licensure, Takeda plans to import and distribute 50 million doses starting in the first half of 2021. This represents Moderna's first clinical trial in Japan, aiming to enhance the country's COVID-19 vaccination efforts.
Moderna (Nasdaq: MRNA) and Uber (NYSE: UBER) have announced a partnership to enhance COVID-19 vaccine uptake. The collaboration will begin with providing vaccine safety information through Uber's app and will explore options like in-app ride scheduling for immunization appointments. Uber previously committed to offering 10 million free or discounted rides to facilitate access to vaccines, especially in underserved communities. Both companies aim to expand this initiative globally, reinforcing vaccine education and accessibility efforts.